Mervyn Turner, Ph.D., is appointed as a director. Dr. Turneraccumulated over 25 years of experience at Merck Research Laboratoriesin pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years, he was head of worldwide licensing and external research at Merck, during a period of rapid expansion in Merck’s partnering activities. He became Merck’s first Chief Strategy Officer and a member of the senior executive team in 2008, before retiring from the company in 2011. Dr. Turnerreceived his BS and Ph.D. in Chemistry from the University of Sheffieldin 1970. He also completed his postdoctoral research in biochemistry of histocompatibility at Havard Universityin 1974. Fangyong (Felix) Du, Ph.D., is appointed as a director. Dr. Dujoined Adageneas Vice President of Technology Developmentin January 2012and has served as Chief Technology Officer since May 2019. Dr. Duhas over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. Dr. Duworked at Affomixfrom October 2009to July 2010and Illumina from July 2010to January 2012, and then joined the Company in January 2012as the Vice President of Technology Development. Dr. Dureceived his Ph.D. degree in biology from the California Institute of Technologyin 2001 and his bachelor’s degree and master’s degree in physiology and biophysics in 1991 and 1994, respectively, from Peking University. Dr. Dualso completed his postdoctoral research from Yale University. Yumeng Wang, replaces Lefei Sunas a director immediately prior to filing of the annual report of the Company for the year of 2022 (the “Annual Report”), as designated by General Atlantic Singapore AI Pte. Ltd.pursuant to Adagene’s current effective memorandum and articles of association. Ms. Wangis a vice president at General Atlantic, primarily responsible for investments in healthcare and life sciences sectors. Prior to joining General Atlantic, Ms. Wangserved as an equity research analyst at The Hongkong and Shanghai Banking Corporation, mainly focusing on the healthcare sector. Ms. Wangalso serves as a non-executive director of Ocumension Therapeutics(1477.HK) and Biotheus Inc. Ms. Wangreceived her bachelor’s degree in business administration in June 2013and her master's degree in biotechnology in 2021 from The Hong Kong University of Science and Technology.
- As a result of Yumeng Wang’s replacement of
Lefei Sun, he has resigned from the Board. Additionally, Yuwen Liuhas resigned from the Board and audit committee of the Board effective upon filing of the Annual Report, due to expiration of her initial appointment as a director and an audit committee member. Adageneappreciates the service of Ms. Liuand her contributions to the Board.
- Each of
Lefei Sunand Yuwen Liuhas confirmed that there is no disagreement with the Board and there is no matter relating to his or her resignation that needs to be brought to the attention of the shareholders of the Company.
“We are excited to welcome Drs. Turner and Du and
For more information, please visit: https://investor.adagene.com.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated clinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor & Media Contact
Ami Knoefler Adagene650-739-9952 firstname.lastname@example.org
Source: Adagene Inc.